Studies on the reactive site of the cystatin superfamily using recombinant cystatin A mutants Evidence that the QVVAG region is not essential for cysteine proteinase inhibitory activities by Nikawa, Takeshi et al.
Volume 255, number 2, 309-314 FEB 07621 September 1989 
Studies on 
Evidence that 
the reactive site of the cystatin superfamily using 
recombinant cystatin A mutants 
the QVVAG region is not essential for cysteine proteinase 
inhibitory activities 
Takeshi Nikawa, Takae Towatari, Yoshimasa Ike* and Nobuhiko Katunuma 
Division of Enzyme Chemistry, The Institute for Enzyme Research, The University of Tokushima, Tokushima 770 and 
*Central Research institute Mitsui Toatsu Chemical inc., Biotechnology Laboratory, Mobara, Chiba 297, Japan 
Received 7August 1989 
For study of the inhibition mechanism of the cystatin superfamily, cystatin A artificial mutants were obtained in which 
a well-conserved QW.4G region in the cystatin superfamily was changed to KWAG or QYTAG and these mutants 
were then expressed in E. co&. For this, genes with these sequences were synthesized enzymatically from 11 ohgodeoxy- 
nucleotides and expressed under the tat promoter gene of the E. co/i plasmids. The products expressed were then purified 
on Sephadex G-50 and HPLC DEAE9PW columns. The substitutions in cystatin A were confirmed by the amino acid 
compositions, N-terminal amino acid sequences and elution positions on ion-exchange chromatography of the products. 
The K, values of these products for the cysteine proteinases, papain and cathepsins B, H and L, were determined in 
comparison with those of wild type r~ombinant cystatin A. Results showed that the cystatin A mutants had similar 
inhibitor activities to those of wild type recombinant cystatin A. Namely replacement of amino acids in the QVVAG 
sequence of cystatin A did not significantly affect the inhibitory activities on these proteinases. The results suggest hat 
the QWAG region is less important than the N-terminal region of cystatin for inhibitory activities on cysteine 
proteinases. 
Cystatin A; Cystatin superfamily; Cysteine proteinase inhibitor; Cystatin A mutant 
1. INTRODUCTION 
Recently many endogenous cysteine proteinase 
inhibitors have been purified from various animal 
tissues. In our laboratory cystatin (Y and p were 
purified from rat liver and these amino acid se- 
quences were determined [ 1,2]. Then amino acid 
sequences of human cystatin A and B were deter- 
mined by Green and Ritonja et al. [3,4]. Several 
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lines of evidence suggest that endogenous in- 
hibitors of cysteine proteinases play a significant 
role in control of intracellular proteolysis. There 
are two well-conserved regions in the amino acid 
sequences of the cystatin superfamily: glycine4 in 
the N-terminal region and the Q46V47V48A4gG50 se- 
quence in the middle portion of cystatin A (amino 
acid sequence numbers of cystatin A). These sites 
have been presumed to be important from the 
following reported findings. On formation of a 
mixed disulfide between cysteine3 and glutathione 
cystatin ,& lost its inhibitory activities [5]. Chicken 
cystatin lost its inhibitory activities on removal of 
its N-terminal region [6f. The truncated c-Ha-ras 
product, ~21, containing the QWAG sequence is 
an effective inhibitor of cathepsin L [7]. Recently, 
the three-dimensional structure of chicken cystatin 
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was determined by X-ray crystallographic analysis, 
and results suggested that the N-terminus of 
chicken cystatin is adjacent to the QVVAG se- 
quence and that N-terminal glycine is complemen- 
tary to the active site of papain [S]. But there is no 
direct proof that the QVVAG sequence is impor- 
tam for the inhibitory activity. 
those of wild type recombinant cystatin A. These 
results suggest that the QVVAG region is less im- 
portant than the N-terminal region for these in- 
hibitory activities. The QVVAG region might be 
involved in stabilization of the interaction between 
cysteine proteinases and their inhibitors. 
Cystatin A (12 kDa) is a member of the cystatin 
superfamily [9] and is mainly located in the epider- 
mis and in leukocytes [lo, 1 I]. In this study, 
cystatin A and its artificial mutants in which 
QVVAG was replaced by KVVAG or QVTAG 
could be expressed in E. cob by a similar method 
to that used in the case of cystatin LY 1121. Then the 
products expressed were purified and their in- 
hibitory activities on the cysteine proteinases, pa- 
pain and cathepsins B, H and L were examined. 
Results showed that the artificial cystatin A 
mutants showed similar inhibitory activities to 
2. MATERIALS AND METHODS 
2.1. Materials 
E. coli strains MC 1061 and HB 101 were used for transfor- 
mation with cloning and expression of plasmids, respectively. 
Plasmid pBR322 was used for cloning the synthetic gene 
fragments. Plasmid pKK223-3 for expression of the synthetic 
gene was obtained commercially. Rat cathepsins B, H and L 
were purified as described [13-151. Papain (EC 3.4.22.2) was 
purchased from Sigma. Aminomethylcoumarin substrates were 
purchased from the Peptide Institute (Osaka). Sodium am- 
picillin was purchased from Meiji Seika Kaisha. 
2.2. Chemical synthesis of the oligomers 
The 11 oligomers were synthesized by the phosphoramidite 
k (1) I_ 
I 1 10 20 Met lie Pro Gly Gly Leu Ser Glu Ala Lys Pro Ala Thi Pro Glu lie Gin Glu lie Val Asp Lys Vat Lys Pro Gin CyStatin A : AATTCATGATCCCGGGTGGTCTGTCTGAAGCTAAACCGGCTACTCCGGAAATC~AGGAAATCGT TIG ACAAAGTTAAACCGCAG 
I 
GTACTAGGGCCCACCAGACAGACTTCGATT GCCGATGAGGCCTTTAGGTCCTTTAGCAACTGTTTCAATTTGGCGTC 
P 
I---- @) ----I- (7) 
(2) 
Leu Glu Glu ?yys Thr Asn Glu Thr Tyr Gly Lys Leu Glu 
CTGGAAGAAAAAACTAACGAAACfTACGGTACGGTAAACTGGAAGCTGTTCAGTACAAAA 
GACCTT~ TTT TTTGATTGC GAATGCCATnGACCTTCGACAAGTCATGTTTTGA 
GTCCAACAACGACCA TGATTGATGTGTAG 
I- (8) 
Lys Val Val Ala Gly Gln Val _T& Ala Gly 
O-K cystatin A : GGTTGTTGCTGGT V-T wstatin A : CAGGTTACTGCTGGT 
TTCCAACAACGACCA GTCCAATGACGACCA 
Lys Tyr &t His Leu LYS Val Phe LYS SW LW pro GIY Gin ASO GIu 
AAAGTTCGTGCTGGTGACA 
LYO ?sn LYS Asp Asp Glu LcO Thr Gly Phe 
++A ACAAAGACGACGAACTGACTGGTTTCTAGTAG 
3 
I 
G~CTGCTGCTTGACTGACCAAAGATCATCCTA 
(11) - 
Fig. 1. Design of synthetic gene fragments based on the amino acid sequence of cystatin A and its mutants. The recognition sites of 
EcoRI and BarnHI were placed at the 5’- and 3’-ends of the gene, respectively. A tandem translation stop codon was inserted at the 
3’-end. The DNA fragment length is 74 to 32 bases, average 61 bases (upper strand) and 51 bases (lower strand). The individual 
oligodeoxyribonucleotides synthesized chemically are named fragments l- 11. Enzymatic joining points are indicated by lines. Large 
letters show the QVVAG amino acid sequence of cystatin A and the mutated sequences KVVAG (Q-K cystatin A) and QVTAG (V-T 
cystatin A). 
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method [ 161 in an automatic DNA synthesizer (Applied 
Biosystems, Inc.). The product was removed from the solid sup- 
port and purified by PAGE. The main product was extracted 
from the gel and precipitated by ethanol 
2.3. Design of fhe gene 
Chemical synthesis of the cystatin A gene and its expression 
in E. coli have been reported by Kaji et al. [17]. But we designed 
11 long length overlapping ohgodeoxynucleotide fragments 
based on the amino acid sequence of cystatin A [18] according 
to the codon usage of E. coli [ 191 as shown in fig. I. The DNA 
fragment length was 74 to 32 bases, average 61 bases (upper 
strand) and 51 bases (lower strand). The recognition sites of 
EcoRI and BumHI were placed at the 5 ‘- and 3 ‘-end of the 
gene, respectively. As the N-terminal amino acid of cystatin A 
is methionine, an additional methionine codon was not 
necessary for initiation. A tandem translation stop codon was 
incorporated at the C-terminal. 
2.4. Assembly of gene fragments and cloning in E. coli 
The assembly was performed as shown in fig.2. Fragments 1, 
6 and 7 were mixed, phosphorylated and annealed. Similarly, 
fragments 2 and 8 were mixed, phosphorylated and annealed. 
These two annealed mixtures were then ligated to make segment 
Fig.2. Assembly of the chemically synthesized DNA fragments and construction of the expression plasmid for the cystatin A gene under 
tat promoter control. The fragments were phosphorylated, annealed and ligated to make a cystatin A gene. This synthesized cystatin 
A gene was introduced between the EcoRI and BamHI sites of pBR322 which had been digested with these restriction enzymes. The 
EcoRI-Hind111 fragment of this plasmid containing the cystatin A gene was introduced into expression ptasmid pKK223-3. 
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A, which was purified by ethanol precipitation. Segment B was 
prepared in the same manner. Segments A and B were then 
ligated followed by the total cystatin A gene and this gene was 
purified by ethanol precipitation. The chemically and 
biochemically synthesized cystatin A gene was then ligated to 
pBR322 which had been digested with EcoRI and BarnHI. The 
plasmid was introduced into E. co/i MC1061 and the resulting 
ampicillin-resistant ransformants were screened by colony 
hybridi~tion with radio~beIed oligomer fragment 1 and 11 as 
probes. Restriction enzyme analysis revealed that 10 of the 12 
hybridization positive transformants contained the desired 
EcoRI-BumHI fragment corresponding to the synthetic gene of 
cystatin A. The nucleotide sequence of the EcoRI-BarnHI frag- 
ment was confirmed by the method of Maxam and Gilbert [ZO]. 
2.5. Construction of the expression pIasmid for cystotin A 
The EcoRI-Hind111 fragment of pTPI-1028 containing the 
EcoRI-BumHI fragment was ligated to the E. coli tat expres- 
sion plasmid (pKK223-3) at the EcoRI and Hind111 sites by a 
one-step reaction with T4-DNA ligase (fig.2) [21]. This plasmid 
was transferred to E. coli HBlOl and the resulting transfor- 
mants were screened by the same method as described above. 
One of the positive transformants, pAE2007, was employed for 
purification of cystatin A. 
2.6. Modification of cystotin A amino acid 
We changed two amino acids in the QVVAG region of 
cystatin A to hydrophilic amino acids, Q4’” to K (Q-K cystatin 
A) and V“* to T (V-T cystatin A) by assembly and cloning of 
the synthesized DNA fragments as shown in figs 1 and 2. The 
nucIeotide sequences of the EcoRI-BamHI fragments from 
these two kinds of plasmids were confirmed by the method of 
Maxam and Gilbert. In addition two kinds of expression 
plasmids of the modified cystatin A gene were constructed in 
the same way as in fig.2 [expression plasmid phE8 (Q-K 
cystatin A) and pApE2 (V-T cystatin A)]. 
2.1. Purification and characterization of recombinant cystotin 
A and its mutants expressed by E. coli 
The expression plasmid, pAE2007 (wild type recombinant 
cystatin A) was grown at 37°C for 16 h in L-broth (1% trypsin, 
0.5% yeast extract (Difco), 1% NaCl and 40 fig/ml ampicillin). 
The cells were harvested by centrifugation at 10000 x g for 
30 min, frozen and thawed twice and suspended in 5 vols of 
25 mM Tris-HCI buffer, pH 7.5, containing 0.15 M NaCI. This 
suspension was shaken in a vortex mixer operated at full speed 
for 1 min and centrifuged at 20000 x g for 15 min at 4°C. The 
supernatant was applied to a Sephadex G-50 column 
equilibrated with the same Tris-WC1 buffer. Fractions showing 
inhibitory activities on papain were pooled. After concentration 
by ultrafiltration using a YM-10 membrane (Diaflo), they were 
dialyzed overnight against 10 mM Tris-HCI buffer, pH 7.5. The 
dialysates ware further purified by HPLC on DEAE-5PW 
(Toyo Soda Inc.). 
The other expression plasmids, pbE8 (Q-K cystatin A) and 
pA,dE2 (V-T cystatin A), were cultured and purified in the same 
way as the expression plasmid pAE2007. 
The inhibitory activities of recombinant cystatin A and its 
mutants on the cysteine proteinases, papain and cathepsins B, 
H and L were assayed fluorometrically using 
aminomethylcoumarin substrates according to the method of 
Green et al. 131. Fluorescence was monitored in a fluorescence 
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spectrometer (Hitachi 650-1OMs). Emission at 460 nm was 
measured with excitation at 370 nm. The Ki values of inhibitors 
were determined from Lineweaver-Burk plots. 
Amino acid analysis was performed with a Hitachi 835 amino 
acid analyzer after hydrolysis with 6 N HCI in a sealed tube at 
110°C for 24 h. N-terminal amino acid sequence analysis of 
recombinant cystatin A and its mutants were performed with an 
automated gas-phase sequencer (Applied Biosystems, Model 
470A) after desalting by reverse-phase HPLC on COSMOSIL 
X4-300 (Jasco). PTH-amino acids produced in the sequencer 
were analyzed in an Applied Biosystems, Model 12OA analyzer. 
3. RESULTS 
3.1. Western Matting analysis 
The crude preparations of recombinant cystatin 
A and its mutants were subjected to 15% SDS- 
PAGE followed by a Sartoblott-II immunoblot- 
ting system (Sartorius), using rabbit antiserum 
against rat skin cystatin cy. The recombinant 
cystatin A and its mutants were visualized with 
goat anti-IgG Fab ’ conjugated peroxidase (MDL) 
and Konica Immunostain Kits. The expressed pro- 
ducts showed mobilities in 15% SDS-PAGE cor- 
responding to about 12 kDa as predicted from 
their genes (data not shown). 
3.2. Analysis by SDS gel electrophoresis 
Samples of 3 pg of the purified cystatins were 
subjected to 15% SDS-PAGE analysis. Each gave 
a single band with a mobility corresponding to 
12 kDa which was stained with Coomassie brilliant 
blue (fig.3). The yield of purified product by our 
procedure was about 0.5 mg of protein per gram 
wet weight of cells. 
3.2. ~hromatographi~ separation of the three 
kinds of recombinant cystatin As 
The amino acid compositions of the cystatin A 
mutants are compared with that of the wild type 
recombinant cystatin A in table 1. Substitutions of 
amino acids, Q46 to K and V4* to T, were detected. 
Wild type recombinant cystatin A, Q-K cystatin A 
and V-T cystatin A were separated at different 
positions in 75 mM, 37.5 mM and 55 mM NaCl on 
HPLC on a DEAE-SPW column (fig.4). 
Moreover, we confirmed that the sequence of their 
10 N-terminal amino acids was MIPGGLSEAK. 
3.3. rnhibit~on profiles of the three kinds of 
recombinant cystatin As 
The Ki values of recombinant cystatin A and its 
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Fig.3. SDS-electrophoresis of purified recombinant cystatin A 
and its artificial mutants. Samples of 3 ,q3 of purified 
recombinant cystatin A and its mutants were subjected to 15% 
SDS-PAGE. They gave a single band of 12 kDa when stained 
with Coomassie brilliant blue (lanes: 1, marker; 2, recombinant 
cystatin A; 3, Q-K cystatin A; 4, V-T cyst&in A). 
Table 1 
Amino acid composition of wild type recombinant cystatin A 
and its artificial mutants 
Wild type Q-K V-T RP 
cystatin A cystatin A cystatin A 
Asx 
Thr 
Ser 
Glx 
Gly 
Ala 
Cys 
Vat 
Met 
Be 
Leu 
Tyr 
Phe 
Lys 
His 
Arg 
Pro 
Total 
11.0 (1l)b 
6.5 ( 7) 
2.1 ( 2) 
14.7 (15) 
8.4 ( 8) 
5.6 ( 6) 
0.2 ( 0) 
8.7 ( 9) 
1.3 ( 1) 
3.8 ( 4) 
8.0 ( 8) 
3.7 ( 4) 
2.2 ( 2) 
12.0 (12) 
1.3 ( 1) 
1.1 ( 1) 
4.8 ( 5) 
96 
11.1 (11) 
6.6 ( 7) 
1.9 ( 2) 
13.8 (14)l’ 
8.4 ( 8) 
5.5 ( 6) 
0.1 ( 0) 
8.5 ( 9) 
1.1 ( 1) 
3.9 ( 4) 
8.1 ( 8) 
5.5 ( 6) 
2.1 ( 2) 
12.9 (13)f’ 
1.1 ( 1) 
1.1 ( 1) 
4.9 ( 5) 
98 
11.2 (11) 11 
7.7 ( 8)TC 7 
2.0 ( 2) 2 
14.6 (15) 15 
8.4 ( 8) 8 
5.5 ( 6) 5 
0.1 ( 0) 0 
7.6 ( 8)l’ 9 
1.8 ( 2) 2 
3.8 ( 4) 4 
8.6 ( 9) 8 
6.0 ( 6) 6 
2.4 ( 2) 2 
12.0 (12) 12 
1.1 ( 1) 1 
1.0 ( 1) 1 
4.8 ( 5) 5 
100 98 
a Taken from the data presented in [15] 
b Values in parentheses are nearest integers 
’ Upward and downward arrows show differences due to 
amino acid substitutions in cystatin A mutants 
Values were calculated as numbers of residues per molecule 
Fig.4. Purification of recombinant cystatin A and its artificial 
mutants by HPLC on DEAE-SPW. When applied to a HPLC 
DIME-SPW column, recombinant cystatin A (A), Q-K cystatin 
A (B) and V-T cystatin A (C) were eluted with 75 mM, 37.5 mM 
and 55 mM NaCl, respectively. 
Table 2 
Comparison of Ki’ values of wild type recombinant cystatin A 
and its artificial mutants for various cysteine proteinases 
Proteinase Substrate Kr (nM) 
Wild type Q-K cys- V-T cys- 
cystatin A tatin A tatin A 
Papain Z-Phe-Arg-MCA 
(PH 7.0) 5.4 2.3 5.7 
Cathepsin Bb Z-Phe-Arg-MCA 
(PH 6.0) 140 226 143 
Cathepsin Hb Arg-MCA 
@H 7.0) 40 165 31 
Cathepsin Lb Z-Phe-Arg-MCA 
(PH 5.5) 1.6 0.6 5.6 
a Ki values were determined from Lineweaver-Burk plots for 
noncom~titive inhibition 
b Rat liver cathepsins 
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mutants for various cysteine proteinases are com- 
pared in table 2. No significant differences were 
found in the Ki values of these three cystatin As. 
These results indicated that substitutions in the 
QVVAG region did not affect their inhibitory ac- 
tivities appreciably. 
4. DISCUSSION 
We used long fragments of 74 to 32 bases for 
designing the cystatin A gene and ligated the 
fragments containing the cystatin A gene into the 
E. co/i tat expression plasmid by a one-step reac- 
tion. So the yield of purified recombinant cystatin 
A was about 0.5 mg per gram wet weight of cells. 
Some previous evidence suggested that the 
QVVAG region might be important for the in- 
hibitory activities of cysteine proteinase. For ex- 
ample, the QVVAG region in the cystatin 
superfamily is well-conserved in the one- 
dimensional structure. The smallest peptide, Z-Q- 
V-V-A-G-OMe showed some inhibitory activity on 
papain and cathepsin B [22]. Moreover N- 
truncated oryzacystatin lacking G5 and retaining 
QVVAG inhibited papain as efficiently as the full- 
length oryzacystatin [23]. But there have been o 
direct studies on whether substitution of amino 
acids in this region caused significant changes in 
the activities. We found that replacement of amino 
acids in the QVVAG sequence of cystatin A did 
not significantly affect the inhibitory activity on 
papain or cathepsin B, H or L. Judging from 
Bode’s docking model of a chicken cystatin-papain 
complex based on the X-ray crystal structure [B] 
and inhibition of papain by N-terminally truncated 
forms of chicken cystatin [6], the QVVAG region 
might play a role in stabilizing the complex bet- 
ween papain and chicken cystatin, while the N- 
terminal region should be essential for inhibitory 
activity. Our results provide evidence in support of 
this model. We presumed that the substitutions 
QVVAG to KVVAG and QVTAG would not 
change the hairpin loop-like structure, but that 
other substitutions that would change the hairpin 
loop-like structure might decrease the inhibitory 
activity. We conclude from this study that the 
QVVAG region is less important than the N- 
terminal region for cysteine proteinase inhibitory 
activities. 
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